Nutraceutical value of citrus flavanones and their implications in cardiovascular disease

Nutrients

Volumn 9, Issue 5, 2017, Pages

  Testai, Lara ^a   Calderone, Vincenzo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cardiovascular benefit; Citrus flavonoids; Nutraceutical value

Indexed keywords

ANTHOCYANIN; APOLIPOPROTEIN A; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL ACYLTRANSFERASE; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERIODICTYOL; FLAVANONE; GELATINASE B; HESPERETIN; HESPERIDIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; NARINGENIN; NITRIC OXIDE; NUTRACEUTICAL; POTASSIUM CHANNEL; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; FLAVANONE DERIVATIVE;

ANTI ISCHAEMIC ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CITRUS FRUIT; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; ENDOTHELIAL DYSFUNCTION; GLUCOSE TOLERANCE; HEART MUSCLE METABOLISM; HUMAN; HYPERTENSION; INTESTINE FLORA; INTRACELLULAR SIGNALING; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; VASODILATOR ACTIVITY; ANALYSIS; CHEMISTRY; CITRUS; DIETARY SUPPLEMENT; FRUIT;

CARDIOVASCULAR DISEASES; CITRUS; DIETARY SUPPLEMENTS; FLAVANONES; FRUIT; HUMANS;

EID: 85019610372     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu9050502     Document Type: Review

References (80)

1. Mendis, S.; Puska, P.; Norrving, B. Global Atlas on Cardiovascular Disease Prevention and Control; WHO: Geneva, Switzerland, 2017.
2. Butler, J.; Tahhan, A.S.; Georgiopoulou, V.V.; Kelkar, A.; Lee, M.; Khan, B.; Peterson, E.; Fonarow, G.C.; Kalogeropoulos, A.P.; Gheorghiade, M. Trends in characteristics of cardiovascular clinical trials 2001-2012. Am. Heart J. 2015, 170, 263-272. [CrossRef] [PubMed]
3. Moran, A.E.; Forouzanfar, M.H.; Roth, G.A.; Mensah, G.A.; Ezzati, M.; Murray, C.J.; Naghavi, M. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: The Global Burden of Disease 2010 study. Circulation 2014, 129, 1483-1492. [CrossRef] [PubMed]
4. Shashank, K.; Abhay, K.P. Chemistry and Biological Activities of Flavonoids: An Overview. Sci. World J. 2013, 2013, 1-16.
5. Peterson, J.J.; Dwyer, J.T.; Beecher, G.R.; Bhagwat, S.A.; Gabhardt, S.E.; Haytowitz, D.B.; Holden, J.M. Flavanones in oranges, tangerines (mandarins), tangors and tangelos: A compilation and review of the data from the analytical literature. J. Food Compos. Anal. 2006, 19, S66-S73. [CrossRef]
6. Bharti, S.; Rani, N.; Krishnamurthy, B.; Arya, D.S. Preclinical evidence for the pharmacological actions of naringin: A review. Planta Med. 2014, 80, 437-451. [CrossRef] [PubMed]
7. Chanet, A.; Milenkovic, D.; Manach, C.; Mazur, A.; Morand, C. Citrus flavanones: What is their role in cardiovascular protection? J. Agric. Food Chem. 2012, 60, 8809-8822. [CrossRef] [PubMed]
8. Tomas-Barberan, F.A.; Clifford, M.N. Flavanones, chalcones and dihydrochalcones. Nature, occurrence and dietary burden. J. Sci. Food Agric. 2000, 80, 1073-1080. [CrossRef]
9. Ross, S.A.; Ziska, D.S.; Zhao, K.; ElSohly, M.A. Variance of common flavonoids by brand of grapefruit juice. Fitoterapia 2000, 71, 154-161. [CrossRef]
10. Zamora-Ros, R.; Andres-Lacueva, C.; Lamuela-Raventós, R.M.; Berenguer, T.; Jakszyn, P.; Barricarte, A.; Ardanaz, E.; Amiano, P.; Dorronsoro, M.; Larrañaga, N.; et al. Estimation of dietary sources and flavonoid intake in a Spanish adult population (EPIC-Spain). J. Am. Diet. Assoc. 2010, 110, 390-398. [CrossRef] [PubMed]
11. Grosso, G.; Galvano, F.; Mistretta, A.; Marventano, S.; Nolfo, F.; Calabrese, G.; Buscemi, S.; Drago, F.; Veronesi, U.; Scuderi, A. Red orange: Experimental models and epidemiological evidence of its benefits on human health. Oxid. Med. Cell. Longev. 2013, 2013, 157240. [CrossRef] [PubMed]
12. Dauchet, L.; Amouyel, P.; Dallongeville, J. Fruit and vegetable consumption and risk of stroke:A meta-analysis of cohort studies. Neurology 2005, 65, 1193-1197. [CrossRef] [PubMed]
13. Dauchet, L.; Amouyel, P.; Hercberg, S.; Dallongeville, J. Fruit and vegetable consumption and risk of coronary heart disease: A meta-analysis of cohort studies. J. Nutr. 2006, 136, 2588-2593. [PubMed]
14. He, F.J.; Nowson, C.A.; MacGregor, G.A. Fruit and vegetable consumption and stroke: Meta-analysis of cohort studies. Lancet 2006, 367, 320-326. [CrossRef]
15. He, F.J.; Nowson, C.A.; Lucas, M.; MacGregor, G.A. Increased consumption of fruit and vegetables is related to a reduced risk of coronary heart disease: Meta-analysis of cohort studies. J. Hum. Hypertens. 2007, 21, 717-728. [CrossRef] [PubMed]
16. Cassidy, A.; Rimm, E.B.; O’Reilly, E.J.; Logroscino, G.; Kay, C.; Chiuve, S.E.; Rexrode, K.M. Dietary flavonoids and risk of stroke in women. Stroke 2012, 43, 946-951. [CrossRef] [PubMed]
17. Knekt, P.; Kumpulainen, J.; Järvinen, R.; Rissanen, H.; Heliövaara, M.; Reunanen, A.; Hakulinen, T.; Aromaa, A. Flavonoid intake and risk of chronic diseases. Am. J. Clin. Nutr. 2002, 76, 560-568. [PubMed]
18. Yamada, T.; Hayasaka, S.; Shibata, Y.; Ojima, T.; Saegusa, T.; Gotoh, T.; Ishikawa, S.; Nakamura, Y.; Kayaba, K.; Jichi Medical School Cohort Study Group. Frequency of citrus fruit intake is associated with the incidence of cardiovascular disease: The Jichi Medical School cohort study. J. Epidemiol. 2011, 21, 169-175. [CrossRef] [PubMed]
19. Wang, X.; Ouyang, Y.Y.; Liu, J.; Zhao, G. Flavonoid intake and risk of CVD: A systematic review and meta-analysis of prospective cohort studies. Br. J. Nutr. 2014, 111, 1-11. [CrossRef] [PubMed]
20. Onakpoya, I.; O’Sullivan, J.; Heneghan, C.; Thompson, M. The Effect of Grapefruits (Citrus paradisi) on Body Weight and Cardiovascular Risk Factors: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Crit. Rev. Food Sci. Nutr. 2017, 57, 602-612. [CrossRef] [PubMed]
21. Cassidy, A.; O’Reilly, É.J.; Kay, C.; Sampson, L.; Franz, M.; Forman, J.P.; Curhan, G.; Rimm, E.B. Habitual intake of flavonoid subclasses and incident hypertension in adults. Am. J. Clin. Nutr. 2011, 93, 338-347. [CrossRef] [PubMed]
22. Grosso, G.; Stepaniak, U.; Micek, A.; Stefler, D.; Bobak, M.; Pająk, A. Dietary polyphenols are inversely associated with metabolic syndrome in Polish adults of the HAPIEE study. Eur. J. Nutr. 2016, in press. [CrossRef] [PubMed]
23. Reshef, N.; Hayari, Y.; Goren, C.; Boaz, M.; Madar, Z.; Knobler, H. Antihypertensive effect of sweetie fruit in patients with stage I hypertension. Am. J. Hypertens. 2005, 18, 1360-1363. [CrossRef] [PubMed]
24. Morand, C.; Dubray, C.; Milenkovic, D.; Lioger, D.; Martin, J.F.; Scalbert, A.; Mazur, A. Hesperidin contributes to the vascular protective effects of orange juice: A randomized crossover study in healthy volunteers. Am. J. Clin. Nutr. 2011, 93, 73-80. [CrossRef] [PubMed]
25. Rizza, S.; Muniyappa, R.; Iantorno, M.; Kim, J.A.; Chen, H.; Pullikotil, P.; Senese, N.; Tesauro, M.; Lauro, D.; Cardillo, C.; et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J. Clin. Endocrinol. Metab. 2011, 96, E782-E792. [CrossRef] [PubMed]
26. Roohbakhsh, A.; Parhiz, H.; Soltani, F.; Rezaee, R.; Iranshahi, M. Molecular mechanisms behind the biological effects of hesperidin and hesperetin for the prevention of cancer and cardiovascular diseases. Life Sci. 2015, 124, 64-74. [CrossRef] [PubMed]
27. Teede, H.J.; McGrath, B.P.; DeSilva, L.; Cehun, M.; Fassoulakis, A.; Nestel, P.J. Isoflavones reduce arterial stiffness: A placebo-controlled study in men and postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 1066-1071. [CrossRef] [PubMed]
28. Lajous, M.; Rossignol, E.; Fagherazzi, G.; Perquier, F.; Scalbert, A.; Clavel-Chapelon, F.; Boutron-Ruault, M.C. Flavonoid intake and incident hypertension in women. Am. J. Clin. Nutr. 2016, 103, 1091-1098. [CrossRef] [PubMed]
29. Jung, U.J.; Kim, H.J.; Lee, J.S.; Lee, M.K.; Kim, H.O.; Park, E.J.; Kim, H.K.; Jeong, T.S.; Choi, M.S. Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects. Clin. Nutr. 2003, 22, 561-568. [CrossRef]
30. Mulero, J.; Bernabé, J.; Cerdá, B.; García-Viguera, C.; Moreno, D.A.; Albaladejo, M.D.; Avilés, F.; Parra, S.; Abellán, J.; Zafrilla, P. Variations on cardiovascular risk factors in metabolic syndrome after consume of a citrus-based juice. Clin. Nutr. 2012, 31, 372-377. [CrossRef] [PubMed]
31. Constans, J.; Bennetau-Pelissero, C.; Martin, J.F.; Rock, E.; Mazur, A.; Bedel, A.; Morand, C.; Bérard, A.M. Marked antioxidant effect of orange juice intake and its phytomicronutrients in a preliminary randomized cross-over trial on mild hypercholesterolemic men. Clin. Nutr. 2015, 34, 1093-1100. [CrossRef] [PubMed]
32. Toth, P.P.; Patti, A.M.; Nikolic, D.; Giglio, R.V.; Castellino, G.; Biancucci, T.; Geraci, F.; David, S.; Montalto, G.; Rizvi, A.; et al. Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study. Front. Pharmacol. 2016, 6, 299. [CrossRef] [PubMed]
33. Demonty, I.; Lin, Y.; Zebregs, Y.E.; Vermeer, M.A.; van der Knaap, H.C.; Jäkel, M.; Trautwein, E.A. The citrus flavonoids hesperidin and naringin do not affect serum cholesterol in moderately hypercholesterolemic men and women. J. Nutr. 2010, 140, 1615-1620. [CrossRef]
34. Elavarasan, J.; Velusamy, P.; Ganesan, T.; Ramakrishnan, S.K.; Rajasekaran, D.; Periandavan, K. Hesperidin-mediated expression of Nrf2 and upregulation of antioxidant status in senescent rat heart. J. Pharm. Pharmacol. 2012, 64, 1472-1482. [CrossRef] [PubMed]
35. Bleakley, C.; Hamilton, P.K.; Pumb, R.; Harbinson, M.; McVeigh, G.E. Endothelial Function in Hypertension:Victim or Culprit? J. Clin. Hypertens. (Greenwich) 2015, 17, 651-654. [CrossRef] [PubMed]
36. Habauzit, V.; Verny, M.A.; Milenkovic, D.; Barber-Chamoux, N.; Mazur, A.; Dubray, C.; Morand, C. Flavanones protect from arterial stiffness in postmenopausal women consuming grapefruit juice for 6 mo:A randomized, controlled, crossover trial. Am. J. Clin. Nutr. 2015, 102, 66-74. [CrossRef] [PubMed]
37. Curtis, P.J.; Potter, J.; Kroon, P.A.; Wilson, P.; Dhatariya, K.; Sampson, M.; Cassidy, A. Vascular function and atherosclerosis progression after 1 y of flavonoid intake in statin-treated postmenopausal women with type 2 diabetes: A double-blind randomized controlled trial. Am. J. Clin. Nutr. 2013, 97, 936-942. [CrossRef] [PubMed]
38. Dohadwala, M.M.; Holbrook, M.; Hamburg, N.M.; Shenouda, S.M.; Chung, W.B.; Titas, M.; Kluge, M.A.; Wang, N.; Palmisano, J.; Milbury, P.E.; et al. Effects of cranberry juice consumption on vascular function in patients with coronary artery disease. Am. J. Clin. Nutr. 2011, 93, 934-940. [CrossRef] [PubMed]
39. Nestel, P.; Fujii, A.; Zhang, L. An isoflavone metabolite reduces arterial stiffness and blood pressure in overweight men and postmenopausal women. Atherosclerosis 2007, 192, 184-189. [CrossRef] [PubMed]
40. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members, An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-full report. J. Clin. Lipidol. 2014, 8, 29-60.
41. Naci, H.; Brugts, J.J.; Fleurence, R.; Tsoi, B.; Toor, H.; Ades, A.E. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: A network meta-analysis of placebo-controlled and active-comparator trials. Eur. J. Prev. Cardiol. 2013, 20, 641-657. [CrossRef] [PubMed]
42. Orhan, I.E.; Nabavi, S.F.; Daglia, M.; Tenore, G.C.; Mansouri, K.; Nabavi, S.M. Naringenin and atherosclerosis:A review of literature. Curr. Pharm. Biotechnol. 2015, 16, 245-251. [CrossRef] [PubMed]
43. Choe, S.C.; Kim, H.S.; Jeong, T.S.; Bok, S.H.; Park, Y.B. Naringin has an antiatherogenic effect with the inhibition of intercellular adhesion molecule-1 in hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol. 2001, 38, 947-955. [CrossRef] [PubMed]
44. Lee, C.H.; Jeong, T.S.; Choi, Y.K.; Hyun, B.H.; Oh, G.T.; Kim, E.H.; Kim, J.R.; Han, J.I.; Bok, S.H. Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits. Biochem. Biophys. Res. Commun. 2001, 284, 681-688. [CrossRef] [PubMed]
45. Chanet, A.; Milenkovic, D.; Deval, C.; Potier, M.; Constans, J.; Mazur, A.; Bennetau-Pelissero, C.; Morand, C.; Bérard, A.M. Naringin, the major grapefruit flavonoid, specifically affects atherosclerosis development in diet-induced hypercholesterolemia in mice. J. Nutr. Biochem. 2012, 23, 469-477. [CrossRef] [PubMed]
46. Cappello, A.R.; Dolce, V.; Iacopetta, D.; Martello, M.; Fiorillo, M.; Curcio, R.; Muto, L.; Dhanyalayam, D. Bergamot (Citrus bergamia Risso) Flavonoids and Their Potential Benefits in Human Hyperlipidemia and Atherosclerosis: An Overview. Mini Rev. Med. Chem. 2016, 16, 619-629. [CrossRef] [PubMed]
47. Di Donna, L.; Iacopetta, D.; Cappello, A.R.; Gallucci, G.; Martello, E.; Fiorillo, M.; Dolce, V.; Sindona, G. Hypocholesterolaemic activity of 3-hydroxy-3-methyl-glutaryl flavanones enriched fraction from bergamot fruit (Citrus bergamia): “In vivo” studies. J. Funct. Foods 2014, 7, 558-568. [CrossRef]
48. Di Donna, L.; De Luca, G.; Mazzotti, F.; Napoli, A.; Salerno, R.; Taverna, D.; Sindona, G. Statin-like principles of bergamot fruit (Citrus bergamia): Isolation of 3-hydroxymethylglutaryl flavonoid glycosides. J. Nat. Prod. 2009, 72, 1352-1354. [CrossRef] [PubMed]
49. Da Pozzo, E.; Costa, B.; Cavallini, C.; Testai, L.; Martelli, A.; Calderone, V.; Martini, C. The citrus flavanone naringenin protects myocardial cells against age-associated damage. Oxid. Med. Cell. Longev. 2017, in press. [CrossRef] [PubMed]
50. Yamamoto, M.; Jokura, H.; Hashizume, K.; Ominami, H.; Shibuya, Y.; Suzuki, A.; Hase, T.; Shimotoyodome, A. Hesperidin metabolite hesperetin-7-O-glucuronide, but not hesperetin-3'-O-glucuronide, exerts hypotensive, vasodilatory, and anti-inflammatory activities. Food Funct. 2013, 4, 1346-1351. [CrossRef] [PubMed]
51. Liu, Y.; Su, W.W.; Wang, S.; Li, P.B. Naringin inhibits chemokine production in an LPS-induced RAW 264.7 macrophage cell line. Mol. Med. Rep. 2012, 6, 1343-1350. [PubMed]
52. Park, H.Y.; Kim, G.Y.; Choi, Y.H. Naringenin attenuates the release of pro-inflammatory mediators from lipopolysaccharide-stimulated BV2 microglia by inactivating nuclear factor-_B and inhibiting mitogen-activated protein kinases. Int. J. Mol. Med. 2012, 30, 204-210. [PubMed]
53. Giménez-Bastida, J.A.; González-Sarrías, A.; Vallejo, F.; Espín, J.C.; Tomás-Barberán, F.A. Hesperetin and its sulfate and glucuronide metabolites inhibit TNF-_ induced human aortic endothelial cell migration and decrease plasminogen activator inhibitor-1 (PAI-1) levels. Food Funct. 2015, 7, 118-126. [CrossRef] [PubMed]
54. Raso, G.M.; Meli, R.; Di Carlo, G.; Pacilio, M.; Di Carlo, R. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci. 2001, 68, 921-931. [CrossRef]
55. Tsai, S.H.; Lin-Shiau, S.Y.; Lin, J.K. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol. 1999, 126, 673-680. [CrossRef] [PubMed]
56. Hämäläinen, M.; Nieminen, R.; Vuorela, P.; Heinonen, M.; Moilanen, E. Anti-inflammatory effects of flavonoids: Genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediat. Inflamm. 2007, 2007, 45673.
57. Lee, E.J.; Kim, D.I.; Kim, W.J.; Moon, S.K. Naringin inhibits matrix metalloproteinase-9 expression and AKT phosphorylation in tumor necrosis factor-alpha-induced vascular smooth muscle cells. Mol. Nutr. Food Res. 2009, 53, 1582-1591. [CrossRef] [PubMed]
58. Yamamoto, M.; Suzuki, A.; Hase, T. Short-term effects of glucosyl hesperidin and hesperetin on blood pressure and vascular endothelial function in spontaneously hypertensive rats. J. Nutr. Sci. Vitaminol. 2008, 54, 95-98. [CrossRef] [PubMed]
59. Yamamoto, M.; Jokura, H.; Suzuki, A.; Hase, T.; Shimotoyodome, A. Effects of continuous ingestion of hesperidin and glucosyl hesperidin on vascular gene expression in spontaneously hypertensive rats. J. Nutr. Sci. Vitaminol. 2013, 59, 470-473. [CrossRef] [PubMed]
60. Yamada, M.; Tanabe, F.; Arai, N.; Mitsuzumi, H.; Miwa, Y.; Kubota, M.; Chaen, H.; Kibata, M. Bioavailability of glucosyl hesperidin in rats. Biosci. Biotechnol. Biochem. 2006, 70, 1386-1394. [CrossRef] [PubMed]
61. Liu, Y.; Niu, L.; Cui, L.; Hou, X.; Li, J.; Zhang, X.; Zhang, M. Hesperetin inhibits rat coronary constriction by inhibiting Ca(2+) influx and enhancing voltage-gated K(+) channel currents of the myocytes. Eur. J. Pharmacol. 2014, 735, 193-201. [CrossRef] [PubMed]
62. Saponara, S.; Testai, L.; Iozzi, D.; Martinotti, E.; Martelli, A.; Chericoni, S.; Sgaragli, G.; Fusi, F.; Calderone, V. (+/??)-Naringenin as large conductance Ca(2+)-activated K+ (BKCa) channel opener in vascular smooth muscle cells. Br. J. Pharmacol. 2006, 149, 1013-1021. [CrossRef] [PubMed]
63. Calderone, V.; Chericoni, S.; Martinelli, C.; Testai, L.; Nardi, A.; Morelli, I.; Breschi, M.C.; Martinotti, E. Vasorelaxing effects of flavonoids: Investigation on the possible involvement of potassium channels. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 370, 290-298. [CrossRef] [PubMed]
64. Ramón Sánchez de Rojas, V.; Somoza, B.; Ortega, T.; Villar, A.M.; Tejerina, T. Vasodilatory effect in rat aorta of eriodictyol obtained from Satureja obovata. Planta Med. 1999, 65, 234-238. [CrossRef] [PubMed]
65. Lee, S.E.; Yang, H.; Son, G.W.; Park, H.R.; Park, C.S.; Jin, Y.H.; Park, Y.S. Eriodictyol Protects Endothelial Cells against Oxidative Stress-Induced Cell Death through Modulating ERK/Nrf2/ARE-Dependent Heme Oxygenase-1 Expression. Int. J. Mol. Sci. 2015, 16, 14526-14539. [CrossRef] [PubMed]
66. Testai, L.; Martelli, A.; Cristofaro, M.; Breschi, M.C.; Calderone, V. Cardioprotective effects of different flavonoids against myocardial ischaemia/reperfusion injury in Langendorff-perfused rat hearts. J. Pharm. Pharmacol. 2013, 65, 750-756. [CrossRef] [PubMed]
67. Testai, L.; Martelli, A.; Marino, A.; D’Antongiovanni, V.; Ciregia, F.; Giusti, L.; Lucacchini, A.; Chericoni, S.; Breschi, M.C.; Calderone, V. The activation of mitochondrial BK potassium channels contributes to the protective effects of naringenin against myocardial ischemia/reperfusion injury. Biochem. Pharmacol. 2013, 85, 1634-1643. [CrossRef] [PubMed]
68. Testai, L. Flavonoids and mitochondrial pharmacology: A new paradigm for cardioprotection. Life Sci. 2015, 135, 68-76. [CrossRef] [PubMed]
69. Yang, Z.; Liu, Y.; Deng, W.; Dai, J.; Li, F.; Yuan, Y.; Wu, Q.; Zhou, H.; Bian, Z.; Tang, Q. Hesperetin attenuates mitochondria-dependent apoptosis in lipopolysaccharide-induced H9C2 cardiomyocytes. Mol. Med. Rep. 2014, 9, 1941-1946. [CrossRef] [PubMed]
70. Sharma, A.K.; Bharti, S.; Ojha, S.; Bhatia, J.; Kumar, N.; Ray, R.; Kumari, S.; Arya, D.S. Up-regulation of PPAR, heat shock protein-27 and -72 by naringin attenuates insulin resistance, _-cell dysfunction, hepatic steatosis and kidney damage in a rat model of type 2 diabetes. Br. J. Nutr. 2011, 106, 1713-1723. [CrossRef] [PubMed]
71. Cho, K.W.; Kim, Y.O.; Andrade, J.E.; Burgess, J.R.; Kim, Y.C. Dietary naringenin increases hepatic peroxisome proliferators-activated receptor αprotein expression and decreases plasma triglyceride and adiposity in rats. Eur. J. Nutr. 2011, 50, 81-88. [CrossRef] [PubMed]
72. Jung, U.J.; Lee, M.K.; Park, Y.B.; Kang, M.A.; Choi, M.S. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int. J. Biochem. Cell Biol. 2006, 38, 1134-1145. [CrossRef] [PubMed]
73. Sundaram, R.; Shanthi, P.; Sachdanandam, P. Effect of tangeretin, a polymethoxylated flavone on glucose metabolism in streptozotocin-induced diabetic rats. Phytomedicine 2014, 21, 793-799. [CrossRef] [PubMed]
74. Manach, C.; Scalbert, A.; Morand, C.; Remesy, C.; Jimenez, L. Polyphenols: Food sources and bioavailability. Am. J. Clin. Nutr. 2004, 79, 727-747. [PubMed]
75. Urpi-Sarda, M.; Rothwell, J.; Morand, C.; Manach, C. Bioavailability of flavanones. In Flavonoids and Related Compounds: Bioavailability and Function; Spencer, J., Crozier, A., Eds.; CRC Press: Boca Raton, FL, USA, 2012; pp. 1-65.
76. Silveira, J.Q.; Cesar, T.B.; Manthey, J.A.; Baldwin, E.A.; Bai, J.; Raithore, S. Pharmacokinetics of flavanone glycosides after ingestion of single doses of fresh-squeezed orange juice versus commercially processed orange juice in healthy humans. J. Agric. Food Chem. 2014, 62, 12576-12584. [CrossRef] [PubMed]
77. Ozdal, T.; Sela, D.A.; Xiao, J.; Boyacioglu, D.; Chen, F.; Capanoglu, E. The Reciprocal Interactions between Polyphenols and Gut Microbiota and Effects on Bioaccessibility. Nutrients 2016, 8, 78. [CrossRef] [PubMed]
78. Rowland, I.; Gibson, G.; Heinken, A.; Scott, K.; Swann, J.; Thiele, I.; Tuohy, K. Gut microbiota functions:Metabolism of nutrients and other food components. Eur. J. Nutr. 2017, in press. [CrossRef] [PubMed]
79. Shen, L.; Hong-Fang, J. Intestinal microbiota and metabolic diseases: Pharmacological implications. Trends Pharmacol. Sci. 2016, 37, 169-171. [CrossRef] [PubMed]
80. Cassidy, A.; Minihane, A.M. The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids. Am. J. Clin. Nutr. 2017, 105, 10-22. [CrossRef] [PubMed]